Meurs H, Kauffman H F, Koëter G H, Timmermans A, de Vries K
J Allergy Clin Immunol. 1987 Sep;80(3 Pt 1):326-39. doi: 10.1016/0091-6749(87)90039-x.
Allergen challenge of allergic patients with asthma caused various changes in the beta-receptor-adenylate cyclase system of lymphocyte membranes from these patients. These changes included uncoupling and down regulation of beta-adrenergic receptors and nonspecific refractoriness of adenylate cyclase, as demonstrated by reduced responses to isoproterenol (beta 2), histamine (H2), 5'-guanylylimidodiphosphate, and sodium fluoride. Since these changes could be due to desensitization by enhanced plasma levels of catecholamines and/or histamine during the allergic response, we explored the effects of these agonists on the beta-receptor-adenylate cyclase system in vitro with normal lymphocytes. In addition, we assessed the effect of the tumor-promoting phorbol ester, phorbol 12-myristate 13-acetate (PMA), on this system, since phorbol esters have been demonstrated to modulate several receptor systems, presumably via activation of protein kinase C. That both the agonists and PMA may cause refractoriness of lymphocyte adenylate cyclase was demonstrated, but, however, by apparently different mechanisms. The agonists isoproterenol and histamine induced only a specific desensitization of the homologous responses, whereas PMA-induced refractoriness was nonspecific in nature. Radioligand-binding studies demonstrated that both uncoupling and down regulation contributed to the isoproterenol-induced beta-adrenergic hyporesponsiveness, whereas beta-adrenergic receptor uncoupling but not beta-adrenergic receptor down regulation was involved in PMA-induced desensitization. Histamine had no effect on the beta-adrenergic system at all. The data suggest that the agonist-induced changes in the adenylate cyclase system are specifically located at the receptors, whereas PMA-induced refractoriness can be explained by alterations distal to the receptors, presumably at the stimulatory guanine nucleotide regulatory protein. Thus, enhanced levels of catecholamines or histamine could be involved in the development of receptor-specific changes in the lymphocyte adenylate cyclase system of allergic patients with asthma. However, they are unlikely to cause the nonspecific changes distal to the receptors. The latter changes could be induced by physiologic activation of protein kinase C during the allergic response by a still unknown stimulus, possibly via the receptor-mediated turnover of phosphatidylinositol 4,5-diphosphate.
对患有哮喘的过敏患者进行变应原激发试验,会使这些患者淋巴细胞膜的β受体 - 腺苷酸环化酶系统发生各种变化。这些变化包括β肾上腺素能受体的解偶联和下调,以及腺苷酸环化酶的非特异性不应性,这可通过对异丙肾上腺素(β2)、组胺(H2)、5'-鸟苷酰亚胺二磷酸和氟化钠的反应降低来证明。由于这些变化可能是由于过敏反应期间血浆中儿茶酚胺和/或组胺水平升高导致的脱敏作用,我们在体外研究了这些激动剂对正常淋巴细胞β受体 - 腺苷酸环化酶系统的影响。此外,我们评估了促肿瘤佛波酯,佛波醇12 - 肉豆蔻酸酯13 - 乙酸酯(PMA)对该系统的影响,因为已证明佛波酯可能通过激活蛋白激酶C来调节几种受体系统。结果表明,激动剂和PMA均可导致淋巴细胞腺苷酸环化酶的不应性,但显然是通过不同的机制。激动剂异丙肾上腺素和组胺仅诱导同源反应的特异性脱敏,而PMA诱导的不应性本质上是非特异性的。放射性配体结合研究表明,解偶联和下调均导致异丙肾上腺素诱导的β肾上腺素能低反应性,而PMA诱导的脱敏涉及β肾上腺素能受体解偶联而非β肾上腺素能受体下调。组胺对β肾上腺素能系统完全没有影响。数据表明,激动剂诱导的腺苷酸环化酶系统变化特异性地位于受体处,而PMA诱导的不应性可通过受体远端的改变来解释,推测是在刺激性鸟嘌呤核苷酸调节蛋白处。因此,儿茶酚胺或组胺水平升高可能参与患有哮喘的过敏患者淋巴细胞腺苷酸环化酶系统中受体特异性变化的发生。然而,它们不太可能导致受体远端的非特异性变化。后者的变化可能是由过敏反应期间蛋白激酶C的生理激活通过仍未知的刺激诱导的,可能是通过受体介导的磷脂酰肌醇4,5 - 二磷酸的周转。